International Journal of Cancer Management

Published by: Kowsar

Small Cell Lung Cancer in Good Performance Status: A Mono-Center Tunisian Study

Houda El Benna 1 , Azza Gabsi 1 , Nesrine Mejri 1 , * , Soumaya Labidi 1 , Nouha Daoud 1 , Mehdi Afrit 1 and Hamouda Boussen 1
Authors Information
1 Medical Oncology Department, Abderrahmane Mami Hospital, Ariana, Tunisia
Article information
  • International Journal of Cancer Management: February 2018, 11 (2); e9355
  • Published Online: February 24, 2018
  • Article Type: Research Article
  • Received: December 20, 2016
  • Revised: January 25, 2017
  • Accepted: February 10, 2018
  • DOI: 10.5812/ijcm.9355

To Cite: El Benna H , Gabsi A, Mejri N, Labidi S, Daoud N, et al. Small Cell Lung Cancer in Good Performance Status: A Mono-Center Tunisian Study, Int J Cancer Manag. 2018 ; 11(2):e9355. doi: 10.5812/ijcm.9355.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S-19S. doi: 10.1378/chest.12-2363. [PubMed: 23649448].
  • 2. Ben Abdallah M, Zehani S. Registre des Cancers Nord-Tunisie 1995–1998. Tunis: Institut Salah Azaiez; 2004.
  • 3. Varghese AM, Zakowski MF, Yu HA, Won HH, Riely GJ, Krug LM, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9(6):892-6. doi: 10.1097/JTO.0000000000000142. [PubMed: 24828667].
  • 4. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3. 1973;4(2):31-42. [PubMed: 4580860].
  • 5. Fruh M, De Ruysscher D, Popat S, Crino L, Peters S, Felip E, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi99-105. doi: 10.1093/annonc/mdt178. [PubMed: 23813929].
  • 6. Bharti MK, Chauhan A, Kaushal V. Characterıstıcs, Treatment Patterns And Outcomes Of Patıents Wıth Small Cell Lung Cancer - A Retrospectıve Analysıs. IJPSR. 2011;2(8):2206-10.
  • 7. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006;106(11):2428-36. doi: 10.1002/cncr.21884. [PubMed: 16634096].
  • 8. Unalmis , Yasar Z, Buyuksirin M, Polat G, Ucsular FD, Tibet G, et al. Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis. Acta Medica Anatolia. 2015;3(2):47. doi: 10.15824/actamedica.65675.
  • 9. Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol. 2015;33(34):4106-11. doi: 10.1200/JCO.2015.63.7918. [PubMed: 26351333].
  • 10. Postmus PE, Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol. 2001;28(2 Suppl 4):48-52. [PubMed: 11479898].
  • 11. Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17(8):1147-57. doi: 10.1016/S1470-2045(16)30104-8. [PubMed: 27312053].
  • 12. Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev. 2011;37(2):143-50. doi: 10.1016/j.ctrv.2010.05.004. [PubMed: 20580163].
  • 13. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111-6. doi: 10.1038/ng.2405. [PubMed: 22941189].
  • 14. Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33:7503.
  • 15. Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA. Development of molecularly targeted agents and immunotherapies in small cell lung cancer. Eur J Cancer. 2016;60:26-39. doi: 10.1016/j.ejca.2016.03.004. [PubMed: 27060747].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments